Method for preparing TNFR-Fc fusion protein containing target content of impurities

Patent metadata

Field	Value
Publication number	US-10988527-B2
Application number	US-201515541111-A
Country	US
Kind code	B2
Filing date	Dec 29, 2015
Priority date	Dec 31, 2014
Publication date	Apr 27, 2021
Grant date	Apr 27, 2021

Abstract

The present invention relates to a method for preparing a TNFR-Fc fusion protein mixture comprising a target content of hydrophobic chromatogram peak 3, and to a method for adjusting a content of hydrophobic chromatogram peak 3. Specifically, the present invention relates to (a) a method for preparing a TNFR-Fc fusion protein mixture using a hydrophobic interaction chromatograph medium containing an aromatic functional group, which is pre-equilibrated with an equilibration buffer comprising sodium chloride or ammonium sulfate, and a sample comprising a TNFR-Fc fusion protein mixture liquid produced from mammalian cells, and to a method for adjusting the content of hydrophobic chromatogram peak 3 by hydrophobic chromatography using an equilibration buffer containing a predetermined concentration of sodium chloride or ammonium sulfate.

First claim

The invention claimed is:

1. A method for preparing a TNFR-Fc fusion protein mixture comprising a target content of hydrophobic chromatogram peak 3 impurities, wherein the TNFR-Fc fusion protein mixture is a biosimilar to an originator product and the target content of hydrophobic chromatogram peak 3 impurities is adjusted to that of the originator product TNFR-Fc fusion protein mixture, comprising:
(a) injecting a sample comprising a TNFR-Fc fusion protein mixture liquid produced from mammalian cells into a column filled with hydrophobic interaction chromatography (HIC) medium comprising an aromatic functional group, which is pre-equilibrated with an equilibration (EQ) buffer comprising sodium chloride at a concentration of 1 M to 1.4 M or ammonium sulfate at a concentration of 0.45 M to 0.55 M; and
(b) adjusting the content of hydrophobic chromatogram peak 3 impurities by eluting the protein mixture with an elution buffer comprising sodium chloride or ammonium sulfate at the same concentration as that of the equilibration buffer, wherein the concentration of sodium chloride or ammonium sulfate is adjusted to produce the target content of hydrophobic chromatogram peak 3 impurities,
wherein the content of the hydrophobic chromatogram peak 3 impurities of the sample comprising said TNFR-Fc fusion protein mixture of step (a) exceeds 20%, and
wherein the target content of hydrophobic chromatogram peak 3 impurities is 9% to 18%.

2. The method of claim 1 , wherein the aromatic functional group is a phenyl group.

3. The method of claim 1 , wherein the equilibration and elution buffers comprise 7 mM to 15 mM sodium phosphate.

4. The method of claim 1 , wherein the equilibration and elution buffers have a pH of 6 to 8.5.

5. The method of claim 1 , wherein the concentration of sodium chloride of the equilibration buffer is adjusted to produce the target content of hydrophobic chromatogram peak 3 impurities, wherein when the content of hydrophobic chromatogram peak 3 impurities of the sample is in a range of exceeding 20% to less than or equal to 45% and the target content of hydrophobic chromatogram peak 3 impurities is in a range of 2% to 17%, an equilibration buffer comprising sodium chloride at a concentration of 1 M to 1.4 M is used for the equilibration.

6. The method of claim 1 , wherein the concentration of ammonium sulfate of the equilibration buffer is adjusted to produce the target content of hydrophobic chromatogram peak 3 impurities, wherein when the content of the hydrophobic chromatogram peak 3 impurities of the sample exceeds 45% and the target content of the hydrophobic chromatogram peak 3 impurities is in a range of 10% to 20%, an equilibration buffer comprising ammonium sulfate at a concentration of 0.45 M to 0.55 M is used for the equilibration.

7. The method of claim 1 , wherein the sample comprising a TNFR-Fc fusion protein mixture liquid produced from mammalian cells is partially purified by affinity chromatography, anion chromatography, or both.

8. The method of claim 1 , wherein the hydrophobic interaction chromatography consists of sequential processes of loading, equilibration, stripping, and cleaning in place (CIP).

9. A method for adjusting a content of hydrophobic chromatogram peak 3 contained in etanercept, comprising:
pre-equilibrating a hydrophobic interaction chromatography medium with an equilibration buffer comprising sodium chloride at a concentration of 1.0 M to 1.5 M or ammonium sulfate at a concentration of 0.45 M to 0.55 M; and
loading a sample comprising a TNFR-Fc fusion protein prepared to have the same salt concentration as that of the pre-equilibrated hydrophobic interaction chromatography medium;
wherein the content of the hydrophobic chromatogram peak 3 is adjusted to decrease as compared with the loaded sample, and
wherein the hydrophobic chromatogram peak 3 content of a sample with a hydrophobic chromatogram peak 3 content exceeding 20% is decreased to a level of 2% to 17%.

10. The method of claim 9 , wherein the equilibration buffer comprising sodium chloride has a pH of 6 to 8.5.

11. The method of claim 10 , wherein the hydrophobic chromatogram peak 3 content of the sample whose hydrophobic chromatogram peak 3 content exceeds 45% is decreased to a level of 10% to 20%.

12. A method for preparing a biosimilar TNFR-Fc fusion protein mixture comprising a target content of hydrophobic chromatogram peak 3 impurities, comprising:
(a) determining the amount of hydrophobic chromatogram peak 3 impurities in an originator product comprising a TNFR-Fc fusion protein mixture,
(b) injecting a sample of a biosimilar product comprising a TNFR-Fc fusion protein mixture liquid produced from mammalian cells into a column filled with hydrophobic interaction chromatography (HIC) medium comprising an aromatic functional group, which is pre-equilibrated with an equilibration (EQ) buffer comprising sodium chloride or ammonium sulfate; and
(c) adjusting the level of hydrophobic chromatogram peak 3 impurities by eluting the TNFR-Fc fusion protein mixture with an elution buffer comprising sodium chloride or ammonium sulfate at the same concentration as that of the equilibration buffer,
wherein said target content of hydrophobic chromatogram peak 3 impurities is adjusted to that of said originator product, wherein the amount of hydrophobic impurities in the eluate is adjusted by adjusting the concentration of sodium chloride or ammonium sulfate in the elution buffer, and wherein the target content of hydrophobic chromatogram peak 3 impurities in said originator product is between 9% to 18%.

Assignees

• Lg Chemical Ltd

Inventors

• Park Sang Woo
• Lee Hwa Young
• Choi Soon Woong
• Jung Chul Ho

Classifications

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• C07K14/7151 Primary

  for tumor necrosis factor [TNF], for lymphotoxin [LT] · CPC title

• C07K2319/32

  fusions with soluble part of a cell surface receptor, "decoy receptors" · CPC title

• C07K19/00 Primary

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title